Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concomitant inactivation of p53 and Chk2 in breast cancer.

Oncogene - 21 Feb 2002

Sullivan Alexandra, Yuille Martin, Repellin Claire, Reddy Archana, Reelfs Olivier, Bell Alexandra, Dunne Barbara, Gusterson Barry A, Osin Peter, Farrell Paul J, Yulug Isik, Evans Abigail, Ozcelik Tayfun, Gasco Milena, Crook Tim

Abstract excerpt

The structure and expression of the human Rad53 homologue Chk2 was analysed in breast cancer. The previously described silent polymorphism at nucleotide 252 in codon 84 (GAA>GAG) was observed in 5/141 cases. Somatic Chk2 coding mutations were detected in 7/141 cases, these occurring in 4/18 BRCA1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms, Male
Share to Checkpoint Kinase 2
Share to CpG Islands

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to Genes, BRCA1

Share to Germ Cells

Share to Polymorphism, Single-Stranded Conformational

Share to Protein Kinases

Source

Identifiers

PMID: 11857075
DOI: 10.1038/sj.onc.1205207

Genes

BRCA1
BRCA2
GAA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-11857075-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concomitant inactivation of p53 and Chk2 in breast cancer.PMID 11857075Read ↗

Mutation analysis of the CHK2 gene in breast carcinoma and other cancers.Semantic proximity Read ↗

Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers.Semantic proximity Read ↗

CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomasSemantic proximity Read ↗

Alternative splicing and mutation status of CHEK2 in stage III breast cancer.Semantic proximity Read ↗

Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors.Semantic proximity Read ↗

Mutation analysis of the CHK2gene in families with hereditary breast cancerSemantic proximity Read ↗

The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer CellsSemantic proximity Read ↗

p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.Semantic proximity Read ↗

Increased expression of CHK2 in human gastric carcinomas harboring p53 mutations.Semantic proximity Read ↗

Analysis of the CHK2 gene in lymphoid malignancies.Semantic proximity Read ↗

Reduced expression and impaired kinase activity of a Chk2 mutant identified in human lung cancer.Semantic proximity Read ↗

Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.